Allergan PLC. (NYSE:AGN)‘s stock had its “equal weight” rating reaffirmed by Barclays PLC in a report released on Monday.

Several other brokerages have also commented on AGN. Cowen and Company set a $400.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Thursday, June 8th. Citigroup Inc. reiterated a “buy” rating and issued a $280.00 price target on shares of Allergan PLC. in a report on Wednesday, September 20th. Mizuho reduced their price objective on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a research note on Friday, June 9th. Royal Bank Of Canada reiterated a “buy” rating and issued a $285.00 price objective on shares of Allergan PLC. in a research note on Wednesday, September 6th. Finally, Cantor Fitzgerald assumed coverage on shares of Allergan PLC. in a report on Friday, June 16th. They set a “neutral” rating and a $231.00 price objective on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the company. Allergan PLC. presently has an average rating of “Buy” and an average price target of $271.84.

Allergan PLC. (NYSE:AGN) traded up 2.823% during midday trading on Monday, hitting $210.735. 1,235,290 shares of the stock traded hands. The stock has a market cap of $70.45 billion, a PE ratio of 6.421 and a beta of 1.15. The company has a 50-day moving average of $229.79 and a 200-day moving average of $236.07. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period last year, the firm earned $3.35 EPS. On average, equities research analysts anticipate that Allergan PLC. will post $16.22 earnings per share for the current year.

Allergan PLC. announced that its board has approved a share repurchase program on Monday, September 25th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to purchase up to 2.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at

A number of institutional investors have recently modified their holdings of the stock. Waldron LP acquired a new position in shares of Allergan PLC. in the 1st quarter valued at about $348,000. Swiss National Bank grew its holdings in shares of Allergan PLC. by 20.5% during the 1st quarter. Swiss National Bank now owns 1,329,086 shares of the company’s stock worth $317,545,000 after purchasing an additional 226,200 shares during the period. Boulegeris Investments Inc. grew its holdings in shares of Allergan PLC. by 0.8% during the 1st quarter. Boulegeris Investments Inc. now owns 31,480 shares of the company’s stock worth $7,521,000 after purchasing an additional 261 shares during the period. World Asset Management Inc grew its holdings in shares of Allergan PLC. by 3.7% during the 1st quarter. World Asset Management Inc now owns 34,865 shares of the company’s stock worth $8,330,000 after purchasing an additional 1,235 shares during the period. Finally, Morse Asset Management Inc acquired a new stake in Allergan PLC. during the 1st quarter worth approximately $1,584,000. Hedge funds and other institutional investors own 82.03% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.